In order for personalized medicine to become a clinical reality a number of hurdles, both technological and regulatory in nature, need to be addressed. Our ability to image biological and pathological processes at a molecular level using positron emission tomography (PET) imaging offers an unparalleled opportunity to radically reform the manner in which a disease is diagnosed and managed. The degree to which current innovations in PET science will translate into clinical practice, thereby impacting upon personalized medicine, is discussed.
No takes yet. Share an insight, caveat, or question.
Richard Pither (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: